Redeye provides its comprehensive Q1 2026 update for the Swedish listed investment company universe, tracking 21 companies across more than 10 core metrics. In this issue, we analyze a starkly divided sector where market capitalization is split equally between Traditional giants (43%) and Growth & Venture players (43%), alongside a focused Life Science specialist segment (13%). While traditional large-cap listed exposure has significantly outperformed year-to-date, the Growth & Venture space is weathering a deep cyclical storm, trading near its widest discounts relative to Net Asset Value (NAV) since 2017. Our analysis reveals that while operational fundamentals remain distinct, market sentiment and interest rate pressures – rather than structural failure – are driving the current valuation disconnect.
LÄS MER
